{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T10:50:46Z","timestamp":1787482246557,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF- 2016M3A9B6903499"],"award-info":[{"award-number":["NRF- 2016M3A9B6903499"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.canlet.2020.10.003","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T04:07:18Z","timestamp":1602821238000},"page":"54-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["A Novel cytarabine analog evokes synthetic lethality by targeting MK2 in p53-deficient cancer cells"],"prefix":"10.1016","volume":"497","author":[{"given":"Jayoung","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinha","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lak Shin","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4306-7024","authenticated-orcid":false,"given":"Sang Kook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2020.10.003_bib1","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1146\/annurev-med-050913-022545","article-title":"Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors","volume":"66","author":"Lord","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.canlet.2020.10.003_bib2","first-page":"1639","article-title":"Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells","volume":"55","author":"Russell","year":"1995","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2020.10.003_bib3","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1093\/jnci\/88.14.956","article-title":"UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53","volume":"88","author":"Wang","year":"1996","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2020.10.003_bib4","doi-asserted-by":"crossref","first-page":"9092","DOI":"10.1073\/pnas.161281798","article-title":"ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation","volume":"98","author":"Nghiem","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2020.10.003_bib5","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1038\/sj.onc.1208451","article-title":"Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G2 cell cycle checkpoints","volume":"24","author":"Levesque","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2020.10.003_bib6","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/annonc\/mdg240","article-title":"Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites","volume":"14","author":"Fedier","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2020.10.003_bib7","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1101\/gad.1815309","article-title":"The combined status of ATM and p53 link tumor development with therapeutic response","volume":"23","author":"Jiang","year":"2009","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2020.10.003_bib8","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1021\/jm101488z","article-title":"Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents","volume":"54","author":"Charrier","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.canlet.2020.10.003_bib9","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nsmb.2076","article-title":"A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations","volume":"18","author":"Toledo","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.canlet.2020.10.003_bib10","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.canlet.2020.10.003_bib11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.molcel.2004.11.021","article-title":"MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2\/M transition and S phase progression in response to UV irradiation","volume":"17","author":"Manke","year":"2005","journal-title":"Mol. Cell."},{"key":"10.1016\/j.canlet.2020.10.003_bib12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ccr.2006.11.024","article-title":"p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK\/MK2 pathway for survival after DNA damage","volume":"11","author":"Reinhardt","year":"2007","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2020.10.003_bib13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.molcel.2010.09.018","article-title":"DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization","volume":"40","author":"Reinhardt","year":"2010","journal-title":"Mol. Cell."},{"key":"10.1016\/j.canlet.2020.10.003_bib14","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.celrep.2013.10.025","article-title":"A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo","volume":"5","author":"Morandell","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2020.10.003_bib15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrd4010","article-title":"Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases","volume":"12","author":"Jordheim","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2020.10.003_bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbamcr.2014.10.003","article-title":"Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine","volume":"1853","author":"Fiorini","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2020.10.003_bib17","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/ijc.1628","article-title":"Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine","volume":"97","author":"Galmarini","year":"2002","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.canlet.2020.10.003_bib18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1172\/JCI6863","article-title":"Disruption of p53 in human cancer cells alters the responses to therapeutic agents","volume":"104","author":"Bunz","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2020.10.003_bib19","first-page":"149","article-title":"Susceptibility to cytosine arabinoside (Ara-C)-induced cytotoxicity in human leukemia cell lines","volume":"152","author":"Kanno","year":"2004","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.canlet.2020.10.003_bib20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1021\/ol7025558","article-title":"First synthesis of 4'-selenonucleosides showing unusual Southern conformation","volume":"10","author":"Jeong","year":"2008","journal-title":"Org. Lett."},{"key":"10.1016\/j.canlet.2020.10.003_bib21","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1021\/jm900852b","article-title":"Discovery of a new template for anticancer agents: 2'-deoxy-2'-fluoro-4'-selenoarabinofuranosyl-cytosine (2'-F-4'-seleno-ara-C)","volume":"52","author":"Jeong","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.canlet.2020.10.003_bib22","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.bcp.2010.07.026","article-title":"Inhibition of cell growth and potentiation of tumor necrosis factor-alpha (TNF-alpha)-induced apoptosis by a phenanthroindolizidine alkaloid antofine in human colon cancer cells","volume":"80","author":"Min","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2020.10.003_bib23","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.canlet.2020.10.003_bib24","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1158\/1078-0432.CCR-08-3127","article-title":"Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors","volume":"15","author":"Chen","year":"2009","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2020.10.003_bib25","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/sj.onc.1207528","article-title":"Cell death by mitotic catastrophe: a molecular definition","volume":"23","author":"Castedo","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2020.10.003_bib26","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrm3115","article-title":"Mitotic catastrophe: a mechanism for avoiding genomic instability","volume":"12","author":"Vitale","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2020.10.003_bib27","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.canlet.2020.10.003_bib28","first-page":"47","article-title":"Cabozantinib for the treatment of metastatic medullary thyroid carcinoma","volume":"5","author":"Nix","year":"2014","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.canlet.2020.10.003_bib29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11864-017-0444-6","article-title":"Cabozantinib for renal cell carcinoma: current and future paradigms","volume":"18","author":"Abdelaziz","year":"2017","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.canlet.2020.10.003_bib30","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.2013.54.5954","article-title":"Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study","volume":"32","author":"Smith","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2020.10.003_bib31","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1158\/2159-8290.CD-16-0778","article-title":"Cabozantinib eradicates advanced murine prostate cancer by activating antitumor innate immunity","volume":"7","author":"Patnaik","year":"2017","journal-title":"Canc. Discov."},{"key":"10.1016\/j.canlet.2020.10.003_bib32","first-page":"30204","article-title":"Cabozantinib for progressive metastatic castration-resistant prostate cancer following docetaxel: combined analysis of two phase 3 trials","volume":"S2588\u20139311","author":"Sonpavde","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.canlet.2020.10.003_bib33","first-page":"138","article-title":"Review of recent studies on resistance to cytotoxic deoxynucleoside analogues","volume":"1776","author":"Jordheim","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2020.10.003_bib34","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1470-2045(10)70244-8","article-title":"The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer","volume":"12","author":"Jordheim","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2020.10.003_bib35","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1053\/j.gastro.2012.06.006","article-title":"Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma","volume":"143","author":"Marechal","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2020.10.003_bib36","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1158\/1078-0432.CCR-04-0224","article-title":"The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma","volume":"10","author":"Spratlin","year":"2004","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2020.10.003_bib37","doi-asserted-by":"crossref","first-page":"9063","DOI":"10.1038\/sj.onc.1207229","article-title":"Mechanisms of apoptosis induction by nucleoside analogs","volume":"22","author":"Sampath","year":"2003","journal-title":"Oncogene"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383520305012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383520305012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:15:26Z","timestamp":1778742926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383520305012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":37,"alternative-id":["S0304383520305012"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2020.10.003","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Novel cytarabine analog evokes synthetic lethality by targeting MK2 in p53-deficient cancer cells","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2020.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}